BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29113202)

  • 1. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
    Huang JP; Ling K
    Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
    Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
    Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
    Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
    Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.
    Yang Y; Zhao Y; Liao W; Yang J; Wu L; Zheng Z; Yu Y; Zhou W; Li L; Feng J; Wang H; Zhu WG
    Neoplasia; 2009 Apr; 11(4):313-24. PubMed ID: 19308286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
    Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
    Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
    Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
    Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
    Deb G; Thakur VS; Limaye AM; Gupta S
    Mol Carcinog; 2015 Jun; 54(6):485-99. PubMed ID: 24481780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 13. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
    Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y
    Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
    Gong C; Yao S; Gomes AR; Man EP; Lee HJ; Gong G; Chang S; Kim SB; Fujino K; Kim SW; Park SK; Lee JW; Lee MH; ; Khoo US; Lam EW
    Oncogenesis; 2016 Apr; 5(4):e214. PubMed ID: 27043660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions.
    Shi Z; Li Y; Qian X; Hu Y; Liu J; Zhang S; Zhang J
    J Cancer; 2017; 8(15):3037-3048. PubMed ID: 28928895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
    Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
    Biomark Res; 2018; 6():10. PubMed ID: 29556394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.